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Abstract: The incidence of osteoporotic fractures increases with age. Consequently, the global 
prevalence of osteoporotic fractures will increase with the aging of the population. In old 
age, osteoporosis is associated with a substantial burden in terms of morbidity and mortality. 
Nevertheless, osteoporosis in old age continues to be underdiagnosed and undertreated. This may, 
at least partly, be explained by the fact that evidence of the antifracture efficacy of osteoporosis 
treatments comes mainly from randomized controlled trials in postmenopausal women with a 
mean age of 70–75 years. However, in the last years, subgroup analyses of these landmark trials 
have been published investigating the efficacy and safety of osteoporosis treatment in the very 
elderly. Based on this evidence, this narrative review discusses the pharmacological manage-
ment of osteoporosis in the oldest old ($80 years). Because of the high prevalence of calcium 
and/or vitamin D deficiency in old age, these supplements are essential in the management of 
osteoporosis in the elderly people. Adding antiresorptive or anabolic treatments or combina-
tions, thereof, reduces the risk of vertebral fractures even more, at least in the elderly with 
documented osteoporosis. The reduction of hip fracture risk by antiresorptive treatments is less 
convincing, which may be explained by insufficient statistical power in some subanalyses and/or 
a higher impact of nonskeletal risk factors in the occurrence of hip fractures. Compared with 
younger individuals, a larger absolute risk reduction is observed in the elderly because of the 
higher baseline fracture risk. Therefore, the elderly will benefit more of treatment. In addition, 
current osteoporosis therapies also appear to be safe in the elderly. Although more research is 
required to further clarify the effect of osteoporosis drugs in the elderly, especially with respect 
to hip fractures, there is currently sufficient evidence to initiate appropriate treatment in the 
elderly with osteoporosis and osteoporotic fractures.
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Osteoporosis and osteoporotic fractures in old age: 
a challenge
Along with the aging of the population, the incidence of age-associated conditions 
increases, and more attention and resources are required for the management of these 
disorders in the elderly. Osteoporosis is a systemic skeletal disease characterized by 
low bone mass and microarchitectural deterioration of bone tissue, with a consequent 
increase in bone fragility and fracture risk.1 The incidence of osteoporotic fractures 
increases with age, and osteoporosis in old age is a challenge because of the extent 
of the problem and the significant burden in terms of morbidity, mortality, and eco-
nomic cost. Today, the cumulative incidence of hip fractures in women aged 80 years 
is ~30%.2 Vertebral fractures are even more common, with a prevalence of ~20% 
in women aged .75 years and .40% in women aged .80 years.3 In addition, the 
number of nonhip nonvertebral fractures such as fractures of the proximal humerus 
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increases dramatically with age, particularly in women 
aged .80 years.4 Women aged .80 years account for .30% 
of all osteoporotic fractures and even .60% of all nonver-
tebral fractures.5
Age is one of the main determinants of not only the 
absolute risk of fracture, but also the type of osteoporotic 
fracture. Between the ages of 55 and 75 years, postmeno-
pausal women are at more risk of vertebral fractures than 
any other type of fracture, but at the age of .75 years, they 
become increasingly at a risk of hip fracture and other non-
vertebral fractures.6
The burden of osteoporosis will only increase in the future 
because of the aging of the population. In Belgium, it is 
expected that in the next 10 years, the number of osteoporo-
tic fractures will increase with 25%, from ~80.000 per year 
to .98.000 per year.7
Elderly persons with osteoporotic 
fractures are frail
Elderly patients with osteoporotic fractures are not “average” 
elderly persons but should be considered as frail elderly, with 
a high prevalence of underlying comorbidities.8 Indeed, in old 
age, osteoporosis and osteoporotic fractures tend to occur in 
a particularly frail subset of population.9 This frailty will be 
reflected in poor postfracture outcomes, such as mortality, 
functional decline, and loss of quality of life. For example, 
within 1 year after a hip fracture, 40% of patients were unable 
to walk independently, 33% of them were totally dependent 
or in a nursing home, and mortality was ~20%.10–12 Similar 
observations were found, to some extent, in the elderly with 
other types of nonvertebral fractures and even with vertebral 
fractures.13 In patients with hip fracture, this excess mortality 
is not only observed within the first year following the fracture 
but continuously observed in the years thereafter because of 
the underlying comorbidities in these frail elderly.14
Underdiagnosis and undertreatment 
of osteoporosis in old age
Despite the increasing evidence for the high prevalence and 
severity of osteoporosis in the elderly, osteoporosis continues 
to be underdiagnosed and undertreated in old age. Even in 
older individuals admitted to the hospital with documented 
fractures, physicians continue to underuse the available treat-
ment options, particularly in women aged .80 years.15
Since elderly persons with osteoporosis constitute a partic-
ularly frail subset of population, there is an urgent requirement 
for convenient treatment options with documented efficacy and 
safety. Available osteoporosis treatments should be proven to 
be effective in the elderly, not only against vertebral fractures 
but even more so against nonvertebral fractures, as these 
account for most of the morbidity and mortality associated 
with osteoporosis in old age. Treatment options should also be 
proven to be safe in the elderly who are frail, with underlying 
comorbidities, and at an increased risk of adverse events.
Treatment of osteoporosis in the 
oldest old
In the following sections, the existing evidence on efficacy 
and safety of the currently available treatment options for 
osteoporosis in the oldest old ($80 years) is evaluated. Of 
note, nonpharmacological interventions such as fall preven-
tion strategies play an essential role in the management of 
osteoporosis, also in the elderly, but are outside the scope 
of this manuscript.
Calcium and vitamin D supplementation 
in old age
One of the main determinants of bone loss and fracture risk 
in old age is calcium and vitamin D deficiency; therefore, 
combined supplementation of calcium and vitamin D has 
become one of the main components for reducing bone loss 
and fracture risk in old age.
Vitamin D deficiency is commonly defined as a serum 
level of 25-hydroxyvitamin D (25OHD) of ,20 ng/mL, and 
although there is much controversy about this threshold,16 it 
is clear that low levels of 25OHD occur in all age-groups. 
In European countries, for example, 2%–30% of adults 
have a serum 25OHD level of ,10 ng/mL, but this may rise 
to .80% in the institutionalized elderly.17 In fact, a gradual 
decrease of 25OHD is observed from healthy adults over 
independent elderly to institutionalized persons and patients 
with hip fracture.17 Despite the observation that the intestinal 
absorption of vitamin D
3
 and its metabolism into 25OHD and 
the biologically active metabolite 1,25-dihydroxyvitamin D 
(1,25(OH)
2
D
3
) is well preserved in the elderly without liver 
disease or kidney failure, these individuals are at a risk of 
hypovitaminosis D because of low vitamin D dietary intake 
and decreasing capacity of the skin to produce vitamin D
3
, 
together with less outdoor activities and sun exposure.17,18 
Therefore, unsurprisingly, the elderly and especially those in 
institutions have lower levels of 25OHD than that of young 
individuals from the same geographic region.19 Hypovitamin-
osis D lowers the intestinal calcium absorption and leads to a 
negative calcium balance, which may be enhanced by insuf-
ficient dietary calcium intake. This stimulates the secretion of 
parathyroid hormone (PTH; age-related hyperparathyroidism), 
Clinical Interventions in Aging 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1067
Osteoporosis treatment in the very elderly
which enhances bone turnover, advances osteoporosis, and 
increases fracture risk.20 Poor vitamin D status may also 
increase fracture risk by increasing the risk of falling appar-
ently through an effect on muscle strength.21
Adequate vitamin D status is therefore essential in the 
prevention of falls as well as bone loss and osteoporotic 
fractures. In order to reduce the risk of falls, a daily intake 
of 800–1,000 IU of vitamin D is recommended.22 There is 
indeed ample evidence of the effect of vitamin D supple-
mentation at a dose of 800–1,000 IU on fall reduction.23 
Therefore, the International Osteoporosis Foundation and the 
American Geriatrics Society recommend vitamin D supple-
mentation of at least 1,000 IU in the community-dwelling 
and institutionalized elderly.22,24 In older adults, 800–1,000 
IU of vitamin D is the estimated average to reach a serum 
25OHD level of 30 ng/mL (75 nmol/L), which is required to 
reduce the risk of falls and fall-related injuries.22,25 Consider-
able higher doses up to 4,000 IU per day would be required 
to ensure that almost all (92%) older adults reach this level 
of 30 ng/mL.22,24 However, the efficacy of doses .1,000 IU 
per day for falls has not been demonstrated in randomized 
controlled trials (RCTs). For example, in patients with hip 
fracture, a daily intake of 2,000 IU of vitamin D was not more 
effective than 800 IU per day to prevent falls.26 In contrast, it 
has recently been shown that an intermittent very high dose of 
vitamin D such as a single oral dose of 500,000 IU per year 
increases the risk of falls, especially in the first 3 months when 
serum 25OHD level increased to .45 ng/mL (112 nmol/L). 
Furthermore, another recent trial showed that a monthly high 
dose of vitamin D (60,000 IU per month) increased the risk 
of falls compared with 24,000 IU per month.27 Therefore, at 
this time, it is premature to recommend intakes .1,000 IU of 
vitamin D per day for all older adults to prevent falls.22,23
There is much controversy about the threshold level 
of serum 25OHD for bone health and, thus, the optimal 
intake of vitamin D to prevent bone loss and osteoporotic 
fractures. The Institute of Medicine recommends a daily 
intake of 800 IU of vitamin D for those aged $71 years in 
order to achieve a serum 25OHD level of at least 20 ng/mL 
(50 nmol/L) as this meets the requirement of at least 97.5% 
of the population.28,29 In contrast, in its 2011 guideline, the 
Task Force of the Endocrine Society recommends a serum 
25OHD level .30 ng/mL.30 However, a serum 25OHD 
level .20 ng/mL is sufficient to normalize surrogate end-
points of bone health such as 1,25(OH)
2
D
3
, PTH, intestinal 
calcium absorption, and bone mineral density (BMD). There 
is no convincing proof of additional benefit on bone health 
with a serum 25OHD level .30 ng/mL.23
In addition, there is an ongoing intense debate whether 
vitamin D, in combination with calcium, does indeed reduce 
the risk of osteoporotic fractures.31,32 Yet, although it is clear 
that vitamin D alone does not reduce fracture risk,33–36 strong 
scientific evidence supports its beneficial effect in combina-
tion with calcium.34,35 In addition to an insufficient dose of 
calcium and vitamin D supplementation as well as therapeutic 
incompliance, which may be as high as 40%–60% even in 
relatively healthy study participants,37,38 another reason why 
individual RCTs and meta-analyses failed to demonstrate a 
reduction in fracture risk with calcium and vitamin D may 
be the lack of targeting the population at a risk of a negative 
calcium balance and/or vitamin D deficiency.23,39 Indeed, 
calcium and vitamin D supplementation needs to be directed 
to persons with documented or at a risk of calcium and/or 
vitamin D deficiency, which is highly prevalent in people 
aged $75 years and in institutionalized persons.17 A recent 
meta-analysis, for example, found that vitamin D coadmin-
istered with calcium reduced the risk of hip fractures in 
institutionalized, but not in community-dwelling elderly.31
In recent years, safety questions have been raised about 
the use of supplemental calcium with and without vitamin D, 
because of a potential increased cardiovascular risk with 
calcium supplements.40,41 Currently, there is no conclusive 
evidence that calcium supplements increase cardiovascular 
risk. Nevertheless, it seems appropriate to correct calcium 
deficiency preferably by enhancing dietary intake and to 
direct supplementation to the aforementioned subgroups that 
will most benefit from the supplementation. However, indi-
viduals who do not obtain sufficient dietary calcium intake 
should not be advised to avoid calcium supplements because 
of concerns about an increased cardiovascular risk.42
Thus, the combined supplementation of calcium and 
vitamin D has become an essential component to reduce 
bone loss and fracture risk in elderly individuals. However, 
osteoporosis treatment, on top of calcium and vitamin D, 
should be considered in the elderly with osteoporosis 
and osteoporotic fractures. In the following section, the 
evidence on the efficacy (Table 1) and safety (Table 2) of the 
currently available osteoporosis treatments in the oldest old 
is discussed.
Pharmacological osteoporosis treatment 
in old age
Efficacy of osteoporosis drugs
Alendronate
The efficacy of alendronate as an antiresorptive agent was 
established by the Fracture Intervention Trial (FIT). The FIT 
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Osteoporosis treatment in the very elderly
Vertebral Fracture Arm (FIT-I) included postmenopausal 
women with a prevalent vertebral fracture,43 whereas the 
FIT Clinical Fracture Arm (FIT-II) included postmenopausal 
women with a T-score #-1.6 at the femoral neck (mean 
age =70.8 years and 67.7 years, respectively).44 The third 
analysis of the FIT investigated the effect of alendronate in 
postmenopausal women with an existing vertebral fracture 
or with a T-score #-2.5 at the femoral neck, but without 
vertebral fractures (mean age =69.9 years).45
A post hoc analysis of the FIT-I by Ensrud et al has 
evaluated the antifracture efficacy of alendronate in post-
menopausal women with the highest fracture risk.46 This 
analysis included a subgroup of patients aged $75 years 
(range =75–82 years). After 3 years, alendronate significantly 
reduced the risk of vertebral fracture by 38% (relative risk 
[RR] =0.62; 95% confidence interval [CI] =0.41–0.94) in 
women aged $75 years, compared with 51% in the younger 
population (RR =0.49; 95% CI =0.35–0.68). In order to pre-
vent one new vertebral fracture, 8 women aged $75 years 
needed to be treated with alendronate compared with 
9 women aged ,75 years.
The post hoc analysis of the FIT-I by Ensrud et al was 
followed by an analysis based on the pooled data from both 
FIT arms.47 The aim of this analysis by Hochberg et al was to 
calculate age-specific fracture rates by the treatment group (ie, 
55 to ,65 years, 65 to ,70 years, 70 to ,75 years, and 75–85 
years). RR reductions for hip (RR =0.47; 95% CI =0.27–0.81; 
P,0.01) and vertebral (RR =0.55; 95% CI =0.37–0.83; 
P,0.01) fractures were constant among age-groups, with 
an even greater absolute risk reduction as age increases. This 
greater absolute risk reduction was explained by the age-
related increase in fracture risk in the placebo group.47
Finally, a very recent study by Axelsson et al showed that 
alendronate treatment in patients with a mean age of 82.4±8.3 
years with a prior fracture was associated with a reduced hip 
fracture risk (hazard ratio (HR) =0.72; 95% CI =0.61–0.85; 
P,0.001).48 The reduction in hip fracture risk was maintained 
across all age quartiles, and the absolute risk reduction at 5 
years increased substantially by quartile of age.
These results illustrated that alendronate is an effective 
osteoporosis treatment in the elderly with proven vertebral 
and hip fracture reduction and also indicated that the elderly 
who have a higher baseline fracture risk benefit even more 
from osteoporotic treatment than younger persons.46,47
Risedronate
In 1999 and 2000, the Vertebral Efficacy with Risedronate 
Therapy (VERT) trials (VERT – North America [VERT-NA] 
and VERT – Multinational [VERT-MN]) demonstrated the 
efficacy of risedronate to prevent vertebral and nonverte-
bral fractures in postmenopausal women with one or more 
prevalent vertebral fractures (mean age =~70 years).49,50 In 
2001, the Hip Intervention Program (HIP) trial investigated 
the effect of risedronate on hip fracture risk in two different 
arms, of which the first arm included postmenopausal women 
with a mean age of 74 years.51
The second arm of the HIP trial included 3,886 women, 
aged $80 years (mean age =83 years), with at least one 
nonskeletal risk factor for hip fracture (eg, poor gait or a 
propensity to fall) or a low BMD at the femoral neck.51 After 
3 years, no significant reduction in the risk of hip fractures 
was observed (RR =0.8; 95% CI =0.6–1.2; P=0.35). Of note, 
the majority (58%) of the participants were selected based on 
the presence of a nonskeletal risk factor, whereas only 16% 
of them were selected based on low BMD.
A second analysis focusing on the elderly was a pooled 
analysis of the VERT-NA, VERT-MN, and HIP trials by 
Boonen et al.52 This analysis included 1,392 women aged $80 
(mean age =83 years) with osteoporosis (T-score ,-2.5 or 
at least one prevalent vertebral fracture). The risk of ver-
tebral fractures was reduced by 81% (HR =0.19; 95% 
CI =0.09–0.40; P,0.001) after 1 year and by 44% (HR =0.56; 
95% CI =0.39–0.81; P=0.003) after 3 years. For nonvertebral 
fractures, the incidence was not significantly different in the 
treatment group and the placebo group (P=0.66).
This difference in benefit for vertebral versus nonverte-
bral fractures in the elderly in the analyses of both McClung 
et al and Boonen et al might be explained by the fact that 
bisphosphonates impact on BMD, proven by the significant 
reduction of vertebral fractures. However, bisphosphonates 
do not have impact on the nonskeletal risk factors of fractures 
such as gait disturbances, impaired balance, and fall risk. 
These nonskeletal factors are of particular importance in the 
occurrence of nonvertebral fractures, such as hip fractures, 
in the elderly who are more prone to falling.53 In contrast, 
vertebral fractures are often atraumatic, thus less influenced 
by these nonskeletal risk factors. An additional explanation 
for this discrepancy between the older and younger popula-
tion in preventing nonvertebral fractures might be insufficient 
statistical power in the older age-group.52
Zoledronic acid
If administered inappropriately, the intake of oral bisphospho-
nates is associated with well-known gastrointestinal adverse 
events.54 Moreover, adherence to oral bisphosphonates is 
low: ~50% of the patients to whom oral therapy is prescribed 
have discontinued the treatment after 1 year.55 These factors 
make parenteral zoledronic acid an attractive choice in the 
Clinical Interventions in Aging 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1072
vandenbroucke et al
treatment of osteoporosis, especially in the elderly and 
disabled, demented, or frail patients in whom polypharmacy, 
nonadherence, and intolerance are most prevalent.56
The Health Outcomes and Reduced Incidence with 
Zoledronic Acid Once Yearly – Pivotal Fracture Trial 
(HORIZON-PFT) has shown that zoledronic acid is an effec-
tive treatment in postmenopausal osteoporotic women (mean 
age =73 years), with, after 3 years, a significant reduction 
in the risk of vertebral, hip, and nonvertebral fractures.57 
In a subsequent analysis, the HORIZON-Recurrent Fracture 
Trial (HORIZON-RFT) in patients with a surgical repair of a 
low-trauma hip fracture (mean age =74.4 years), zoledronic 
acid significantly reduced the risk of new vertebral and 
nonvertebral fractures.58
In 2010, Boonen et al published a post hoc pooled analysis 
of the HORIZON-PFT and HORIZON-RFT focusing on the 
elderly.56 Inclusion criteria were postmenopausal women aged 
$75 years (mean age =79.4 years) with osteoporosis (T-score 
#-2.5 at the femoral neck or $1 prevalent vertebral or hip frac-
ture). After 3 years, the incidence of vertebral and nonvertebral 
fracture was significantly lower in the zoledronic acid group 
than in the placebo group (HR =0.34; 95% CI =0.21–0.55; 
P,0.001 and HR =0.73; 95% CI =0.6–0.9; P=0.002, respec-
tively). This benefit was comparable with the RR reduction in 
subjects aged ,75 years in the HORIZON-PFT and HORI-
ZON-RFT, presenting zoledronic acid as an effective treat-
ment option for the prevention of vertebral and nonvertebral 
fractures in the elderly. However, in patients aged $75 years, 
the incidence of hip fractures was lower with zoledronic acid, 
but this did not meet statistical significance (HR =0.82; 95% 
CI =0.56–1.2; P=0.297), contrary to the statistical signifi-
cance that was obtained in patients aged ,75 years. Possibly 
the sample size was not statistically powered to detect hip 
fracture risk reduction in this older age-group. An alternative 
explanation is the greater influence of nonskeletal risk factors 
for hip fractures with increasing age.52,56
Denosumab
Denosumab has been established as a safe and effective 
intervention by the FREEDOM trial by Cummings et al, with 
a significant risk reduction of vertebral, hip, and nonvertebral 
fractures in postmenopausal women with a mean age of 
72.3 years.59
A post hoc analysis of the FREEDOM trial was carried out 
by Boonen et al in 2011 to evaluate the effect of denosumab 
in high-risk populations, among which persons aged $75 
years.60 In this age-group (mean age =78.2 years), denosumab 
significantly reduced the risk of hip fractures by 62% (2.3% 
placebo versus 0.9% denosumab; P,0.01). This risk reduc-
tion in elderly patients is comparable with the risk reduction 
in the overall study population of the FREEDOM trial.59
Another analysis of the FREEDOM trial by McClung 
et al in 2012 confirmed that denosumab reduces the 
risk of vertebral fractures to the same extent in subjects 
aged $75 years (RR =0.36; 95% CI =0.25–0.53) as in 
subjects aged ,75 years (RR =0.30; 95% CI =0.22–0.41; 
interaction P-value =0.482).61 Furthermore, the effect on 
nonvertebral fractures was similar in persons aged .75 years 
(RR =0.84; 95% CI =0.63–1.12) and ,75 years (RR =0.78; 
95% CI =0.63–0.96; interaction P-value =0.642).
Thus, denosumab is an effective treatment to prevent 
vertebral and hip fractures in the elderly.60,61 This result 
was in contrast to the bisphosphonates where no significant 
reduction in hip fracture risk could be shown for risedronate 
and zoledronic acid in the elderly, although, as mentioned, 
this might be explained by the lack of statistical power in 
these subgroup analyses.46,47,56 However, it is tempting to 
speculate that this observation of hip fracture reduction 
with denosumab is due to its mechanism of action, which is 
different from the mechanism of action of bisphosphonates, 
with distinct effects on cortical bone.62 Cortical porosity is 
indeed one of the main determinants of nonvertebral fracture 
risk, including hip fracture risk.
Strontium ranelate
The antifracture efficacy of strontium ranelate, which has a 
dual mode of action of both increasing bone formation and 
reducing bone resorption, was established by two trials: the 
Spinal Osteoporosis Therapeutic Intervention (SOTI) trial 
(mean age =69.3 years) and the Treatment of Peripheral 
Osteoporosis (TROPOS; mean age =76.7 years).63,64
A preplanned pooled analysis of both SOTI and TROPOS 
was undertaken by Seeman et al to confirm these results in 
patients aged $80 years (mean age =83.5 years). After 3 years, 
the risk of vertebral fractures was reduced by 32% (RR =0.68; 
95% CI =0.50–0.92) and the risk of nonvertebral fractures was 
reduced by 31% (RR =0.69; 95% CI =0.52–0.92).65 After 5 
years, the risk of vertebral fractures was reduced by 31% (RR 
=0.69; 95% CI =0.52–0.92) and the risk of non-vertebral frac-
tures was reduced by 27% (RR =0.73; 95% CI =0.57–0.95).5 
The number needed to treat to prevent vertebral and nonver-
tebral fractures was lower in women aged $80 years than in 
younger women. This is because a similar RR reduction of 
strontium ranelate in both age-groups will avert more fractures 
in the older age-group that has a higher baseline fracture risk.65 
Statistical significance of hip fracture risk reduction was not 
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reached in both the trials, but these analyses were not designed 
to quantify the reduction in hip fracture risk.5,65 Thus, these 
analyses showed a significant reduction in the risk of both 
vertebral and nonvertebral fractures in persons aged $80 years 
treated with strontium ranelate.
Teriparatide
Daily subcutaneous injections of teriparatide, a biosynthetic 
PTH analog, reduces the risk of vertebral and nonvertebral 
fractures, as shown in the Fracture Prevention Trial (FPT) 
in postmenopausal women with a prior vertebral fracture 
(mean age =69.5 years).66
A prespecified subgroup analysis of the FPT study 
was undertaken in 2006 by Boonen et al to investigate the 
effect of teriparatide in persons aged $75 years (mean 
age =78.3 years).67 In this subgroup, 5.2% in the teriparatide 
group and 15.1% in the placebo group had a new vertebral 
fracture after 19 months (RR =0.35; P,0.05). Treatment-
by-age interaction was not significant (P=0.99), indicating 
that the effect of teriparatide was not statistically different 
in younger versus older patients. Also in the older subgroup, 
3.2% of the elderly women on teriparatide and 4.2% on pla-
cebo had a new nonvertebral fracture (RR =0.75; P=0.661). 
The treatment-by-age interaction was again not significant 
(P=0.42). The nonsignificant effect on nonvertebral fracture 
risk in the very elderly can be explained by the small number 
of nonvertebral fractures in the older subgroup. As a result, 
this analysis was not sufficiently powered to show a statisti-
cally significant reduction in the risk of nonvertebral fractures 
in women aged $75 years or to detect small differences in 
the relative treatment effect on nonvertebral fractures in the 
younger and older subgroups.67 Hip fracture incidence was 
not a primary endpoint of this study.67 Therefore, age does 
not affect the efficacy of teriparatide in preventing vertebral 
and nonvertebral fractures.
Safety of osteoporosis drugs
The large pivotal fracture trials have shown that, in general, 
osteoporosis treatment is well tolerated, with adverse events 
that tend to be mild to moderate. For an in-depth review of 
the adverse reactions in postmenopausal osteoporosis, the 
present study refers to some recent overviews.68,69 However, 
there are limited data on how this applies to the very elderly 
population.70 Issues concerning drug therapy in the very 
elderly include reduced intestinal absorption, metabolism 
and excretion of drugs, concomitant disorders, polyphar-
macy and therapeutic incompliance.69 For example, aging is 
associated with a decline in renal function. As ~50% of the 
bisphosphonates are excreted by the kidney, impaired renal 
function may result in an accumulation of the bisphospho-
nates, which potentially affects their efficacy and safety.71
In the next section, the available evidence on the safety 
of the currently available pharmacological osteoporosis 
therapies in the very elderly is discussed. Table 2 summa-
rizes the most relevant adverse events reported in the clinical 
trials in this population. Antiresorptive therapy may also be 
associated with very rare but severe adverse events, such as 
atypical femoral fractures and osteonecrosis of the jaw. To 
the authors’ knowledge, there is no evidence that these events 
are independently associated with age.72
Alendronate
The post hoc analysis of the FIT-I in postmenopausal women 
aged $75 years46 and the pooled analysis from both the FIT 
arms47 did not report safety data in the very elderly. In the trial 
of Axelsson et al48 in women with a mean age of 82.4 years, 
adverse events such as esophagitis, dyspepsia, and acid reflux 
were not more common in the higher age quartiles than in 
the lower age quartiles.48
Risedronate
Women aged $80 years in the HIP trial51 had a slightly 
higher incidence of death, other serious adverse events, and 
withdrawals due to adverse events as compared to younger 
women. However, the overall frequency and types of adverse 
events, including those involving the upper gastrointestinal 
tract, were similar in the risedronate and placebo groups, 
regardless of age. In addition, in women aged $80 years 
in the pooled analysis of the VERT-NA, VERT-MN, and 
HIP trials,52 adverse events were similar in the risedronate 
and placebo groups. Even in the very elderly with active 
gastrointestinal tract disease at baseline or on aspirin, non-
steroidal anti-inflammatory drugs, or proton pump inhibitors, 
the incidence of upper gastrointestinal adverse events was 
the same in both the treatment groups.
Thus, according to these data, oral bisphosphonates are 
well tolerated in the very elderly and, even in those at a 
high risk of gastrointestinal events, not associated with an 
increased frequency of these adverse events as compared to 
placebo. However, in clinical practice, treatment with oral 
bisphosphonates may be challenging in the very elderly, 
as the stringent intake instructions (eg, to stay upright for 
at least 30 minutes after taking the medication) may be 
difficult for physically or cognitively impaired elderly. 
While, as mentioned, data from RCTs indicated that the 
gastrointestinal side effects of oral bisphosphonates are 
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similar in older and younger individuals, inappropriate 
administration increases the risk of these adverse events.71 
Furthermore, oral osteoporosis medication (together with 
calcium and vitamin D supplementation) increases the pill 
burden in the very elderly, which may lead to lower compli-
ance. An intravenous bisphosphonate, such as zoledronic 
acid, is an alternative in the very elderly that cannot tolerate 
or adhere to oral bisphosphonates.
Zoledronic acid
In the post hoc analysis of the HORIZON-PFT and RFT in 
women aged $75 years,56 the incidence of adverse events and 
postdose symptoms occurring within 3 days of study drug 
infusion, such as pyrexia, myalgia, and influenza-like illness, 
was higher with zoledronic acid than with placebo. However, 
the incidence of serious adverse events and death were similar 
in the two treatment arms. In addition, an increased risk of 
atrial fibrillation, suggested in the HORIZON-PFT,57 which 
could be a concern in the elderly, was not observed in the 
very elderly on zoledronic acid.56
In this post hoc analysis, which excluded individuals 
with a creatinine clearance ,30 mL/min, the incidence of 
renal events, such as an increase in creatinine clearance, was 
similar in the zoledronic acid and the placebo groups.56 There 
were no data in patients with severe kidney impairment. 
Due to some very rare cases of acute renal failure following 
zoledronic acid, the European Medicine Agency (EMA) 
specified that this therapy is contraindicated in patients with 
a creatinine clearance ,35 mL/min.73
Denosumab
In general, denosumab was well tolerated by the subjects in 
the FREEDOM trial.59 In the post hoc analysis in women 
aged $75 years,60 no significant differences were noted in 
the safety profile between placebo- and denosumab-treated 
subjects. The incidences of the adverse events were similar 
to those reported for the overall FREEDOM population. 
Moreover, the treatment efficacy of denosumab was not affected 
by renal function; therefore, the elderly with renal impairment 
will experience the same antifracture efficacy as patients with 
normal renal function.74 However, as the use of denosumab is 
associated with a high rate of severe hypocalcemia in patients 
with advanced chronic kidney disease, close monitoring and 
replacement of calcium and vitamin D are required to avoid 
the development of hypocalcemia in these patients.
Strontium ranelate
The preplanned pooled analysis of SOTI and TROPOS in 
women aged 80–100 years showed that strontium ranelate 
safely reduces the risk of vertebral and nonvertebral frac-
tures during 3 and 5 years.5,65 After 5 years, headaches, 
deep venous thromboembolic events, and seizures were 
significantly more common in the strontium ranelate group, 
but no case of allergic reaction was reported. Treatment 
with strontium ranelate increased the number and quality of 
remaining years of life.5 However, in patients who were frail 
according to the criteria of Fried et al,75 Strontium ranelate 
was associated with a higher incidence of adverse events, 
serious adverse events, emergent adverse events, and with-
drawals due to adverse events as compared to intermediate 
and nonfrail participants.76 Apart from age, this could relate 
to comorbidity, polypharmacy, and frailty itself.
The recent finding of an increased risk of cardiac events, 
including myocardial infarction, has limited the use of 
strontium ranelate in the very elderly.77 This safety concern 
emerged from new safety data from additional clinical studies 
in male osteoporosis and osteoarthritis. The analysis of the 
cardiovascular data led the EMA to recommend a change 
in the indication of strontium ranelate.77 Strontium ranelate 
remains a useful therapeutic alternative in elderly patients 
with severe osteoporosis who are unable to take other 
osteoporosis treatments, but it is contraindicated in those 
with uncontrolled hypertension, established, current or past 
history of ischemic heart disease, peripheral arterial disease, 
and/or cerebrovascular disease.78
Teriparatide
In the post hoc analysis of the FPT in women aged $75 years,67 
there was no increase in adverse events in women treated with 
teriparatide compared with placebo. In contrast, back pain, 
cataract, and pruritus were significantly less common in those 
treated with teriparatide. The treatment-by-age interaction 
($75 years versus ,75 years) was not significant for the 
important adverse events. Only diarrhea was reported more 
frequently, whereas cataract, deafness, pruritus, and weight 
loss were reported less frequently in the older compared to 
the younger age-group. Thus, in the elderly, the safety pro-
file of teriparatide is similar to placebo. In clinical practice, 
the major disadvantages of teriparatide are the cost and the 
daily subcutaneous administration, which may be a burden 
for older patients.
Summary of  safety of osteoporosis drugs
Data from the post hoc and preplanned analyses in the 
very elderly showed that currently available osteoporosis 
therapies are relatively safe, with no significant differences 
in the incidence of most adverse events in the treated group 
compared with the placebo group. Overall, the incidence of 
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adverse events in the very elderly was similar to that reported 
in the general population. However, in real life, specific 
issues such as comorbidity and polypharmacy should be 
taken into account in the very elderly and may influence the 
choice of therapy.
Conclusion
Osteoporosis is one of the most common age-associated 
conditions and a major cause of fracture risk. In old age, 
osteoporosis and osteoporotic fractures tend to occur in 
a particularly frail subset of population. The treatment of 
osteoporosis is of particular concern in the elderly because 
of the substantial burden of osteoporotic fractures in terms 
of morbidity, mortality, and economic cost.
It is never too late to treat osteoporosis, not even in elderly 
patients with the most severe degree of osteoporosis and who 
have already sustained osteoporotic fractures. Calcium and 
vitamin D supplementation is an essential but not sufficient 
component of the management of osteoporosis in old age. 
Adding osteoporosis treatment appears to be safe and reduces 
the risk of fractures even more, at least in older individuals 
with documented osteoporosis and for vertebral fractures, 
and possibly also for hip fractures. Osteoporosis treatment 
may even be more effective in frail elderly patients with 
documented osteoporosis than in younger patients, with more 
fractures averted and even lower numbers to treat, ultimately 
leading to reduced morbidity and even mortality.
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